Insignis Therapeutics Receives Positive FDA Feedback on IN-001 Clinical Program for Needle-Free Anaphylaxis Treatment
November 05, 2024 08:00 ET
|
Insignis Therapeutics, Inc.
Insignis Therapeutics advances IN-001, a needle-free anaphylaxis treatment, following FDA’s positive feedback and Fast Track designation.
Over-the-Counter Drugs Market Projected to Reach USD 213.08 Billion by 2030, Exhibiting a CAGR of 5.93% - Global 2024 Report
November 01, 2024 10:10 ET
|
Research and Markets
Dublin, Nov. 01, 2024 (GLOBE NEWSWIRE) -- The "Over the Counter (OTC) Drugs - Market Insight, Competitive Landscape, and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's...
U.S. OTC Drugs Market Forecast Report 2024-2029: Shares of Key Players, Industry Trends & Statistics, and Growth Forecasts by Product Type, Formulation Type and Distribution Channel
October 22, 2024 11:49 ET
|
Research and Markets
Dublin, Oct. 22, 2024 (GLOBE NEWSWIRE) -- The "United States Over-The-Counter Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024-2029)" report has been added to ...
Insignis Therapeutics Announces Positive Results from Phase 1 Clinical Study of IN-001 Liquid Epinephrine Sublingual Spray for Anaphylaxis
October 07, 2024 08:00 ET
|
Insignis Therapeutics, Inc.
Insignis' Phase 1 trial shows IN-001 spray quickly reaches target epinephrine levels, sustained for 2 hours, offering a reliable needle-free alternative.
Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia
September 16, 2024 08:30 ET
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Nuance Pharma successfully launched Bentrio® nasal spray for protection against airborne particles in Hong Kong and filed request for marketing...
Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark
August 23, 2024 09:01 ET
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Successful launch of Bentrio by Pharma Nordic AS in Norway in 2024Exclusive distribution agreement extended to also include Sweden and Denmark ...
Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances
August 16, 2024 09:01 ET
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Independent analytical testing of Bentrio for > 230 prohibited substances of WADA list found none of themOutcome further confirms Bentrio’s...
Insignis Therapeutics Receives FDA Fast Track Designation for IN-001 for Anaphylaxis Treatment
August 13, 2024 07:30 ET
|
Insignis Therapeutics, Inc.
Insignis’ liquid epinephrine sublingual spray for anaphylaxis, stable and usable under both extreme heat and cold, gains FDA Fast Track designation.
Halberd Corp’s (OTC: HALB) Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test Results
July 24, 2024 08:00 ET
|
Halberd Corp.
Halberd Corp’s (OTC: HALB) Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test Results
Migraine Nasal Spray Market Forecast to Reach $621.6 Million by 2030: Global Analysis by Formulation, Packaging, Dosage, Distribution Channel, and Region
May 16, 2024 09:11 ET
|
Research and Markets
Dublin, May 16, 2024 (GLOBE NEWSWIRE) -- The "Migraine Nasal Spray Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.The...